Foresite Capital Management IV’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Foresite Capital Management IV’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-431,781	Closed	-$5.94M	–	19
2018 Q4	$5.94M	Sell	431,781 -93,219	-18%	-$1.18M	2.73%	13
2018 Q3	$5.24M	Buy	525,000 +279,918	+114%	+$4.6M	1.72%	14
2018 Q2	$4.99M	Buy	+245,082	New	+$5.14M	1.7%	13

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Foresite Capital Management IV's EIDX Position: Q1 2019 in Review

Foresite Capital Management IV sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2019, closing a stake of 431,781 shares — an estimated $5.94M sold.

Foresite Capital Management IV first reported a position in EIDX in Q2 2018 and held it in 3 quarters. The position peaked at $5.94M in Q4 2018. 63 funds tracked by Wall St. Rank hold EIDX as of Q1 2019.

Foresite Capital Management IV reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Foresite Capital Management IV sold 431,781 Eidos Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $5.94M.
Foresite Capital Management IV first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
Foresite Capital Management IV's Eidos Therapeutics, Inc. Common Stock position peaked at $5.94M in Q4 2018.
63 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Foresite Capital Management IV's 13F filing for Q1 2019, filed 14 May 2019.